$RARE

Law firm Holzer & Holzer announces April 6, 2026 lead plaintiff deadlines for class actions against TCPC, MREO, POM, and RARE over alleged material misstatements.

Class action lawsuit filed against Ultragenyx Pharmaceutical alleging false statements about setrusumab efficacy for Osteogenesis Imperfecta treatment based on flawed trial comparisons.

Rosen Law Firm notifies $RARE investors of securities class action alleging materially false statements about setrusumab efficacy in Phase III trials, with April 6, 2026 lead plaintiff deadline.

Securities class action filed against RARE over alleged false statements regarding Phase III clinical trials for setrusumab. Claim deadline April 6, 2026.

Rosen Law Firm files securities class action against Ultragenyx Pharmaceutical ($RARE) alleging false statements about setrusumab efficacy in clinical trials.

Ultragenyx faces securities lawsuit after setrusumab Phase 3 trial failure. Stock fell 42%. Investors must apply for class action lead plaintiff status by April 6, 2026.

Securities class action filed against $RARE for allegedly misrepresenting setrusumab efficacy data. Investors may claim damages; lead plaintiff deadline April 6, 2026.

Four companies face April 6, 2026 lead plaintiff deadline in shareholder lawsuits alleging disclosure violations involving valuations, clinical trials, and fraudulent promotion.

Securities class action filed against $RARE over alleged misstatements about setrusumab drug efficacy. Failed clinical trials triggered 25-42% stock declines. Investor deadline: April 6, 2026.

Ultragenyx Pharmaceutical's stock plunged 42% after failing to disclose setrusumab Phase 3 trial failure, triggering securities litigation with April 6, 2026 lead plaintiff deadline.

Class action filed against Ultragenyx ($RARE) alleging misrepresented setrusumab trial data. Investors purchasing August 2023-December 2025 may recover damages.

Class action suits filed against Ultragenyx and Mereo BioPharma following failed Phase III trials for setrusumab, with stock prices crashing 42.32% and 87.7% respectively.

Class action lawsuit filed against $UGXY alleging securities fraud over misleading setrusumab trial data and OI patient safety disclosures.

Ultragenyx Pharmaceutical faces securities fraud lawsuit after setrusumab trials failed. Stock crashed 42% in December; investors have until April 6, 2026, to join action.

Ultragenyx faces a securities class action alleging misrepresentations about its setrusumab drug's efficacy for osteogenesis imperfecta. Affected investors have until April 6, 2026 to serve as lead plaintiff.

Global skeletal dysplasia market projected to grow from $3.48B (2026) to $5.37B (2032) at 7.42% CAGR, driven by diagnostic advances and innovative therapies.

Ultragenyx Pharmaceutical faces securities lawsuit after setrusumab trial failure caused 42% stock decline. Lead plaintiff deadline April 6, 2026.

Class action lawsuit filed against $UGDX alleging false statements about setrusumab efficacy for Osteogenesis Imperfecta, claiming Phase III results overstated drug benefits.

Law firm Kahn Swick & Foti files class action against $UGXX over failed Phase 3 trial for rare bone disease drug setrusumab. Investors can apply as lead plaintiffs by April 6.

Kahn Swick & Foti, LLC filed class action lawsuits against Navan, Kyndryl, and Ultragenyx for alleged securities disclosure violations. Lead plaintiff applications due April 24, 2026.